The company focuses on developing several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK inhibitors, and PLK inhibitors. Their pipeline includes CYC065 CDK inhibitor, Sapacitabine and seliciclib, CYC682, CYC140 PLK inhibitor, and CYC202. Founded in 1996 by Professor Sir David Lane and joined by Professor David Glover in 1999, Cyclacel Pharmaceuticals aims to address high unmet medical needs in oncology and hematology through a diversified portfolio of novel drug candidates.